Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00939003 · ClinicalTrials.gov registry record · Phase 3
Study of Adalimumab in Patients With Axial Spondyloarthritis
A Phase 3 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 3
- Development phase
- 192
- Enrollment target
NCT00939003: Completed Phase 3 study, sponsored by AbbVie (prior sponsor, Abbott).
NCT00939003 is a Phase 3 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 192 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00939003, a Phase 3 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 192 participants
- Enrollment target
Study Summary
This study will evaluate how well adalimumab works in the short and long term in patients with axial spondyloarthritis who are not diagnosed as having either ankylosing spondylitis or psoriatic arthritis.
Primary Outcome
ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 20 units (on a scale from 0 to 100) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units on a scale from 0 to 100) in the potential remaining domain: * Patient's Global Assessment of disease activity, measured on a visual analog scale (VAS) from 0 (none) to 100 (severe); * Pain, measured by the total back pain VAS from 0 (no pain) to 100 (most sever
Interventions
- BIOLOGICAL Adalimumab
- BIOLOGICAL Placebo
- BIOLOGICAL Open-label Adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2009-07 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
What the finished NCT00939003 record still lists
NCT00939003 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 3 interventions - of which Adalimumab is the first listed.
NCT00939003 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00939003 about?
NCT00939003 is a clinical study titled "Study of Adalimumab in Patients With Axial Spondyloarthritis". This study will evaluate how well adalimumab works in the short and long term in patients with axial spondyloarthritis who are not diagnosed as having either ankylosing spondylitis or psoriatic arthritis.
What is the current status of trial NCT00939003?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 192 participants. The study started on 2009-07. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00939003?
The interventions under investigation include: Adalimumab (BIOLOGICAL), Placebo (BIOLOGICAL), Open-label Adalimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00939003?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00939003's enrollment target sits among peer trials
192 1398th of 2000 higher than 599 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia